全文获取类型
收费全文 | 41423篇 |
免费 | 2695篇 |
国内免费 | 495篇 |
专业分类
耳鼻咽喉 | 885篇 |
儿科学 | 525篇 |
妇产科学 | 597篇 |
基础医学 | 7028篇 |
口腔科学 | 897篇 |
临床医学 | 3347篇 |
内科学 | 7607篇 |
皮肤病学 | 1694篇 |
神经病学 | 2977篇 |
特种医学 | 2974篇 |
外科学 | 5429篇 |
综合类 | 188篇 |
现状与发展 | 1篇 |
一般理论 | 14篇 |
预防医学 | 1495篇 |
眼科学 | 1000篇 |
药学 | 3961篇 |
中国医学 | 547篇 |
肿瘤学 | 3447篇 |
出版年
2023年 | 236篇 |
2022年 | 169篇 |
2021年 | 1364篇 |
2020年 | 832篇 |
2019年 | 1136篇 |
2018年 | 1321篇 |
2017年 | 1119篇 |
2016年 | 1586篇 |
2015年 | 2246篇 |
2014年 | 2560篇 |
2013年 | 2857篇 |
2012年 | 4242篇 |
2011年 | 3919篇 |
2010年 | 2363篇 |
2009年 | 1921篇 |
2008年 | 2580篇 |
2007年 | 2409篇 |
2006年 | 2118篇 |
2005年 | 1824篇 |
2004年 | 1468篇 |
2003年 | 1282篇 |
2002年 | 1062篇 |
2001年 | 661篇 |
2000年 | 538篇 |
1999年 | 447篇 |
1998年 | 198篇 |
1997年 | 142篇 |
1996年 | 98篇 |
1995年 | 109篇 |
1994年 | 86篇 |
1993年 | 64篇 |
1992年 | 160篇 |
1991年 | 168篇 |
1990年 | 121篇 |
1989年 | 133篇 |
1988年 | 114篇 |
1987年 | 119篇 |
1986年 | 102篇 |
1985年 | 89篇 |
1984年 | 80篇 |
1983年 | 61篇 |
1982年 | 42篇 |
1981年 | 46篇 |
1980年 | 33篇 |
1979年 | 51篇 |
1978年 | 53篇 |
1977年 | 42篇 |
1976年 | 35篇 |
1974年 | 33篇 |
1973年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Hyun Cheol Chung MD PhD Yoon-Koo Kang MD PhD Zhendong Chen MD Yuxian Bai MD Wan Zamaniah Wan Ishak MD Byoung Yong Shim MD Young Lee Park MD Dong-Hoe Koo MD PhD Jianwei Lu MD Jianming Xu MD Hong Jae Chon MD Li-Yuan Bai MD Shan Zeng MD Ying Yuan MD Yen-Yang Chen MD Kangsheng Gu MD Wen Yan Zhong PhD Shu Kuang MD Chie-Schin Shih MD Shu-Kui Qin MD PhD 《Cancer》2022,128(5):995-1003
3.
Kim Sung Jin Park Min Uk Chae Han Kyu Nam Wook Kim So Won Yu Hoon Kim Han Gwun Kang Gil Hyun Park Jong Yeon 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(2):403-410
International Journal of Clinical Oncology - Previous studies have shown a relationship between the occurrence and recurrence of prostate cancer; however, this relationship remains controversial.... 相似文献
4.
Cho Nicholas Wang Chencai Raymond Catalina Kaprealian Tania Ji Matthew Salamon Noriko Pope Whitney B. Nghiemphu Phioanh L. Lai Albert Cloughesy Timothy F. Ellingson Benjamin M. 《Journal of neuro-oncology》2020,147(3):643-652
Journal of Neuro-Oncology - There is growing evidence that the subventricular zone (SVZ) plays a key role in glioblastoma (GBM) tumorigenesis. However, little is known regarding how the SVZ, which... 相似文献
5.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
6.
7.
8.
Soo Jin Kim Kyung Hwan Jegal Ji-Hye Im Gyutae Park Suntae Kim Hye Gwang Jeong Il Je Cho Keon Wook Kang 《Cancer chemotherapy and pharmacology》2020,85(4):685-697
CKD-516 (Valecobulin), a vascular-disrupting agent, inhibits microtubule elongation. We evaluated the effect of CKD-516 on lung cancer cells and the underlying molecular mechanisms. The effects of S516, an active metabolite of CKD-516, were evaluated in HUVECs and three lung cancer cell lines and by a microtubule polymerization assay. Tubulin cross-linking was used to identify the binding site of S516 on tubulin, and Western blotting was performed to identify the intracellular pathways leading to cell death. Subcutaneous lung cancer xenograft models were used to assess the in vivo effect of CKD-516 on tumor growth. S516 targeted the colchicine binding site on β-tubulin. In lung cancer cells, S516 increased endoplasmic reticulum (ER) stress and induced reactive oxygen species (ROS) generation by mitochondria and the ER. In addition, CKD-516 monotherapy strongly inhibited the growth of lung cancer xenograft tumors and exerted a synergistic effect with carboplatin. The findings suggest that CKD-516 exerts an anticancer effect in company with inducing ER stress and ROS production via microtubule disruption in lung cancer cells. CKD-516 may thus have therapeutic potential for lung cancer. 相似文献
9.
RongZong Liu WonShik Choi Saket Jain Deepak Dinakaran Xia Xu Woo Hyun Han XiaoHong Yang Darryl D. Glubrecht Ronald B. Moore Hlne Lemieux Roseline Godbout 《Molecular oncology》2020,14(12):3100
Early stage localized prostate cancer (PCa) has an excellent prognosis; however, patient survival drops dramatically when PCa metastasizes. The molecular mechanisms underlying PCa metastasis are complex and remain unclear. Here, we examine the role of a new member of the fatty acid‐binding protein (FABP) family, FABP12, in PCa progression. FABP12 is preferentially amplified and/or overexpressed in metastatic compared to primary tumors from both PCa patients and xenograft animal models. We show that FABP12 concurrently triggers metastatic phenotypes (induced epithelial‐to‐mesenchymal transition (EMT) leading to increased cell motility and invasion) and lipid bioenergetics (increased fatty acid uptake and accumulation, increased ATP production from fatty acid β‐oxidation) in PCa cells, supporting increased reliance on fatty acids for energy production. Mechanistically, we show that FABP12 is a driver of PPARγ activation which, in turn, regulates FABP12''s role in lipid metabolism and PCa progression. Our results point to a novel role for a FABP‐PPAR pathway in promoting PCa metastasis through induction of EMT and lipid bioenergetics.
Abbreviations
- AR
- androgen receptor
- ATP
- adenosine triphosphate
- CN
- copy number
- CPT1
- carnitine palmitoyltransferase I
- CS
- citrate synthase
- EMT
- epithelial–mesenchymal transition
- ET
- electron transfer‐state
- FABP
- fatty acid‐binding protein
- LD
- lipid droplet
- OA
- oleic acid
- PCa
- prostate cancer
- PPAR
- peroxisome proliferator‐activated receptor
- PPRE
- peroxisome proliferator‐activated receptor response element
- TZD
- thiazolidinediones
10.
Eric Wang Sydney X. Lu Alessandro Pastore Xufeng Chen Jochen Imig Stanley Chun-Wei Lee Kathryn Hockemeyer Yohana E. Ghebrechristos Akihide Yoshimi Daichi Inoue Michelle Ki Hana Cho Lillian Bitner Andreas Kloetgen Kuan-Ting Lin Taisuke Uehara Takashi Owa Raoul Tibes Iannis Aifantis 《Cancer cell》2019,35(3):369-384.e7